Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 377-383

  Kardys, Isabella ^a   Oei, Hok Hay S ^a   Hofman, Albert ^a   Oudkerk, Matthijs ^b   Witteman, Jacqueline C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Coronary calcification; Epidemiology; Inflammation; Lipoprotein associated phospholipase A2

Indexed keywords

CALCIUM; ENZYME; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ELECTRON BEAM TOMOGRAPHY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; SCORING SYSTEM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; CALCINOSIS; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; POPULATION SURVEILLANCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947175610     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.004     Document Type: Article

References (22)

1. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
2. Koenig W., Khuseyinova N., Lowel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
3. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 109 (2004) 837-842
4. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
5. MacPhee C.H., Moores K.E., Boyd H.F., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338 Pt 2 (1999) 479-487
6. Khuseyinova N., Imhof A., Rothenbacher D., et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 182 (2005) 181-188
7. Caslake M.J., Packard C.J., Suckling K.E., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
8. Blankenberg S., Stengel D., Rupprecht H.J., et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44 (2003) 1381-1386
9. Winkler K., Winkelmann B.R., Scharnagl H., et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111 (2005) 980-987
10. Brilakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., and Berger P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
11. Iribarren C., Gross M.D., Darbinian J.A., Jacobs Jr. D.R., Sidney S., and Loria C.M. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 25 (2005) 216-221
12. Hofman A., Grobbee D.E., de Jong P.T., and van den Ouweland F.A. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7 (1991) 403-422
13. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte Jr. M., and Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15 (1990) 827-832
14. van Gent C.M., van der Voort H.A., de Bruyn A.M., and Klein F. Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures. Clin Chim Acta 75 (1977) 243-251
15. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
16. Oei H.H., Vliegenthart R., Hofman A., Oudkerk M., and Witteman J.C. Risk factors for coronary calcification in older subjects. The Rotterdam Coronary Calcification Study. Eur Heart J 25 (2004) 48-55
17. Tjoelker L.W., Wilder C., Eberhardt C., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549-553
18. Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1254 (1995) 231-249
19. Schatz I.J., Masaki K., Yano K., Chen R., Rodriguez B.L., and Curb J.D. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358 (2001) 351-355
20. Mattila K., Haavisto M., Rajala S., and Heikinheimo R. Blood pressure and five years survival in the very old. Br Med J (Clin Res Ed) 296 (1988) 887-889
21. Krumholz H.M., Seeman T.E., Merrill S.S., et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 272 (1994) 1335-1340
22. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511